Stereo Imaging Enhances Breast Cancer Detection

BY PATRICE WENDLING

Chicago Bureau

CHICAGO — A novel mammography system called stereoscopic digital mammography dramatically improved the accuracy of lesion detection in breast cancer screening, according to interim data from an ongoing trial in 1,093 women at high risk for developing breast cancer.

Stereoscopic full-field digital mammography significantly reduced the number of false-positive lesion detections by 49% and false-negative findings by 40%, compared with standard full-field digital mammography, David Getty, Ph.D., and his associates reported at the annual meeting of the Radiological Society of North America.

"Stereoscopic mammography is reducing false-positive reports by nearly one-half, and the implication would be that many fewer women would be recalled unnecessarily for diagnostic work-up, resulting in reduced health care costs and patient anxiety,"

he said. "It is also reducing false-negative readings, especially for clustered calcifications, with the implication that detecting more true lesions will result in earlier detection of those that turn out to be cancer."


A stereoscopic mammogram is created by acquiring two digital x-ray images separated by a rotation of the x-ray tube of about 6-10 degrees between the two acquisitions while the breast remains fixed in a compressed position. Dr. Getty compared the experience of reading a stereoscopic

mammogram to watching 3-D movies while wearing red and green glasses.

The two images are presented simultaneously with crossed polarization on two LCD monitors separated by a sheet of glass coated with a material that is 50% reflective and 50% transmissive. This means the image presented on the lower, vertical monitor is transmitted through the glass and the image from the upper, angled monitor is reflected off the top surface of the glass plate. To view the two images, the radiologist wears passive polarized glasses with crosspolarized lenses so that the radiologist's left eye sees only the image on the lower monitor and the right eye sees only the image being reflected off the glass.

The 3-D display monitor used in the study was developed by Planar Systems Inc., Beaverton, Ore., and uses control software developed by Dr. Getty, a division scientist at BBN Technologies, Cambridge, Mass.

The stereoscopic system allows the radiologist to see the internal structure of the



David Getty, Ph.D., wears crosspolarized lenses to view the 3-D image.

breast directly, in depth, which helps overcome the three main problems associated with standard mammography: masking of lesions, mimicry of lesions, and limited volumetric information. Normal breast tissue is separated away from the lesion in depth, thus increasing the lesion's conspicuousness. False positives are reduced because the elements of normal tissue aligned along the line of sight can be seen lying at different depths within the breast, so they don't mimic a focal abnormality. Finally, volumetric information is increased because the radiologist can directly view the 3-D structure of tissue and calcifications within the breast.

Women in the study, at Emory University's Breast Imaging Center in Atlanta, had a standard screening full-field digital exam then a stereoscopic exam consisting of the cranial-caudal and mediolateral oblique screening views. The exams were read independently by different radiologists.

So far, 259 abnormal findings have been identified by one or both modalities, with further clinical work-up exams showing 109 were true lesions and 150 were false positives. Standard mammography missed 40 of the 109 lesions, and stereoscopic mammography failed to detect 24, a 40% reduction in false-negative readings. Of calcified lesions, standard mammography missed nearly half (20 of 41), compared with 4 missed by stereoscopic mammography, a highly significant reduction. For specificity of lesion detection, standard mammography reported 103 of 150 false positives and stereoscopic mammography just 53, a highly significant 49% reduction.

REGISTER NOW!

Family Practice News® & Internal Medicine News®



Boston University School of Medicine

JOINTLY SPONSOR

Endocrinology in the News

A Continuing Medical Education Conference designed for all health care professionals involved in the management of metabolic disorders and other issues related to endocrinology.

April 12 – 13, 2008 Loews Philadelphia Hotel, Philadelphia

Topic Highlights

Preventing Type 2 Diabetes and Cardiovascular Disease: Lessons From Recent Trials

Incretins - What's Here and What's Coming?

Metabolic Syndrome - Why the Controversy?

Should We Care About HDL Cholesterol?

Nutritional Approach to Obesity: High vs. Low Carb Diet?

Conditions and Comorbidities Affecting Thyroid Function Tests

When to Suspect Adrenal Hypertension

Testosterone Replacement and the Aging Baby Boomer

The Differential Diagnosis of Thin Bones

Bisphosphanates and Recombinant PTH: Indications, Benefits and Complications

Vitamin D Therapy - Expanding Clinical Applications

PCOS and Fertility

Estrogen Therapy and the Menopausal Woman

Case Presentations... and more

Tuition

Physicians:

Early Bird: \$450 Early Bird: \$300 After Dec. 1st: \$495 After Dec. 1st: \$325

Accommodations

Loews Philadelphia Hotel (215) 627-1200

Mention the Family Practice News, Internal Medicine News and Boston University School of Medicine group to receive the special rate of \$199 per night.

Educational Needs Addressed: This conference will provide participants with a corpresenting up-to-date information in the diagnosis and management of these disorders illnesses and androgen-related problems such as polycystic ovary syndrome (PCOS).

Educational Objectives: At the conclusion of this conference, participants will be able to:
- Articulate recent advances in the management of metabolic disorders and other endocrinology-related is

- Identify signs and symptoms that suggest metabolic disorders.
- Explain the management and treatment strategies for metabolic disorders, including, but not limited to, diabetes control and complications of thyroid disorders, hypertension, and osteoporosis.

Accreditation: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Boston University School of Medicine and Elsevier/IMNG. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this educational activity for a maximum of **9.5 AMA PRA Category 1 Credit(s)™**. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Check our websites for conference updates.

www.bu.edu/cme • www.familypracticenews.com • www.internalmedicinenews.com

Course Director

Elliot Sternthal, MD Clinical Director of Diabetes Services Boston Medical Center Assistant Professor of Medicine Boston University School of Medicine

Faculty

Shalender Bhasin, MD

Boston Medical Center Boston University School of Medicir

Susan S. Braithwaite, MD

Seth Braunstein, MD, PhD

Andrea Coviello, MD, MSE

Diana Cullum-Dugan, RD, LD

Alan Farwell, MD

Osama Hamdy, MD, PhD

Stephanie Lee, MD, PhD

Alan Malabanan, MD
Beth Israel Deaconess Medical Center

Beth Israel Deaconess Marvard Medical School Norman A. Mazer, MD. PhD

Marie E. McDonnell, MD

George J. Philippides, MD, FACC

Boston University School of Medicine

Ernst J. Schaefer. MD

Vin Tangpricha, MD, PhD

ersity School of Medicine

Andrea L. Utz, MD, PhD arvard University

To register, please contact: **Boston University**

School of Medicine

Continuing Medical Education

715 Albany Street, A305 Boston, MA, 02118

Phone: (617) 638-4605

Toll-free: (800) 688-2475

Fax: (617) 638-4905

E-mail: cme@bu.edu

Website: http://www.bu.edu/cme